Entering a New Era – Prostate Cancer Immuno-Therapy After the FDA Approval for Sipuleucel-T
None
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2011
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/24252 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Entering a New Era – Prostate Cancer Immuno-Therapy After the FDA Approval for Sipuleucel-T
- New Targets and New Drugs for Cancer Treatment: New Small-Structure Drugs Approved by the FDA from 2020 to 2025
- Quality of Life of Patients with Hormone Refractory Prostate Cancer After Gene Therapy
- An FDA for AI? Pitfalls and Plausibility of Approval Regulation for Frontier Artificial Intelligence
- New hematologic markers of immuno-inflammation and Severe perioperative complications after cardiac surgery.
- Focal therapy in prostate cancer /
- Radiation Therapy for Prostate Cancer